Require systemic immunosuppressive therapies (eg, calcineurin inhibitors, methotrexate, mycophenolate, rapamycin, thalidomide, immunosuppressive antibodies such as anti-IL-6 or anti-IL-6 receptor [IL-6R])
Any condition requiring concurrent systemic immunosuppressive therapy
Chronic immunosuppressive therapy
Chronic immunosuppressive therapy
Chronic treatment with corticosteroids or other immunosuppressive therapy
Chronic treatment with corticosteroids or other immunosuppressive agents
Patients who have concurrent conditions resulting in immune compromise, including chronic treatment with corticosteroids or other immunosuppressive agents
Chronic systemic therapy with immunosuppressive agents including corticosteroids.
Ongoing immunosuppressive therapy.
Ongoing immunosuppressive therapy, including systemic or enteric corticosteroids
Ongoing treatment with steroid therapy or other immunosuppressive
Receiving immunosuppressive therapy including chronic steroids (except physiologic maintenance doses), methotrexate, or other known immunosuppressive agents
Ongoing treatment with immunosuppressive drugs
Regular immunosuppressive therapy
TREATMENT WITH SJCAR19: Receiving systemic immunosuppressive therapy in the 14 days prior to CAR T-cell infusion
Systemic therapy with immunosuppressive agents within 7 days before enrollment
Ongoing immunosuppressive treatment at the time of the start of voruciclib therapy, including systemic or enteric corticosteroids except as follows:
Ongoing immunosuppressive therapy other than corticosteroids.
Receiving immunosuppressive therapy
Patients currently treated with systemic immunosuppressive agents, including steroids, are ineligible until 3 weeks after removal from immunosuppressive treatment
A requirement for systemic immunosuppressive therapy for any reason
Patients receiving concomitant immunosuppressive agents for medical condition
Significant active infection or immune deficiency (including chronic use of immunosuppressive drugs)
Patients requiring chronic systemic immunosuppressive medication including pharmacologic dose of glucocorticoids or cyclosporine should be evaluated by the Medical Monitor for enrollment eligibility.
Patients must not have a history of the following immunosuppressive conditions: bone marrow transplantation and/or organ transplants and/or chronic rheumatic conditions that require active immunosuppressive therapy; patients with a history of chronic lymphoid or leukemic malignancies which are not under active therapy (no active therapy within the last 3 months) will be eligible; patients with chronic lymphoid or leukemic malignancies are eligible with or without active disease as long as they have not had treatment within the past three months
Has a history of the following immunosuppressive conditions: bone marrow transplantation, and/or organ transplants and/or chronic rheumatic conditions that require active immunosuppressive therapy; patients with chronic lymphoid/leukemic malignancies that have undergone treatment in the last 3 months will be ineligible
Conditions requiring chronic steroid or immunosuppressive treatment that likely need additional steroid or immunosuppressive treatments in addition to the protocol therapy
Patients must not be receiving active immunosuppressive therapy.
Chronic treatment with corticosteroids or other immunosuppressive agents
Patients on immunosuppressive agents
Receiving immunosuppressive therapy including chronic steroids, methotrexate, or other known immunosuppressive agents
Patients on or requiring immunosuppressive therapies
Patients currently treated with systemic immunosuppressive agents, including steroids, are ineligible until 3 weeks after removal from immunosuppressive treatment
Patients who are receiving cyclosporine, tacrolimus, or other chronic immunosuppressive agents are NOT eligible for participation
Administration of immunosuppressive drugs less than 2 weeks prior to first dose of ERC1671
Systemic immunosuppressive therapy in the past 14 days
Increasing or chronic treatment (> 5 days) with corticosteroids or another immunosuppressive agent
Under active treatment with immunosuppressive agents such as systemic corticosteroids or cyclosporine that cannot be discontinued before starting rRp450 infusions
Patients must not be receiving active immunosuppressive therapy.
received immunosuppressive therapy < 3 months prior to study Day 1
Systemic cytotoxic or immunosuppressive therapy to be administered concomitantly while participating on this study;
Need for ongoing treatment with an immunosuppressive agent
Is currently treated with systemic immunosuppressive agents, including steroids, are ineligible until 3 weeks after removal from immunosuppressive treatment
Chronic treatment with corticosteroids or other immunosuppressive agents
Patients on chronic steroid use or other immunosuppressive agents
Immunosuppressive therapy within 30 days prior to initiation of protocol therapy
Immunosuppressive therapy within 30 days prior to initiation of protocol therapy
Has a diagnosis of immunosuppressive disorder OR is on any other form of immunosuppressive therapy within 7 days prior to transplant admission
Patients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent
Any heart or lung transplant patient on immunosuppressive agents; renal transplant patients are allowed if patient is willing to reduce immunosuppressive agents and understand risk of rejection and possible need to return to dialysis; patients with chronic lymphocytic leukemia (CLL) or other hematologic malignancies are allowed
Patients who require systemic corticosteroid or other immunosuppressive therapy; immunosuppressive therapy must be stopped at least 14 days prior to cell infusion
A requirement for systemic immunosuppressive therapy for any reason
Patients needing chronic, immunosuppressive systemic steroids are excluded
Patients needing chronic, immunosuppressive systemic steroids are excluded
Systemic immunosuppressive therapy for any reason
Active systemic immunosuppressive therapy
Concurrent immunosuppressive therapy and no known immunosuppressive disease other than primary tumour
Ongoing immunosuppressive therapy
Ongoing systemic immunosuppressive therapy other than corticosteroids.
Patients on immunosuppressive therapy including systemic corticosteroids.
Receiving immunosuppressive therapy
Immunosuppressive therapy
Use of systemic immunosuppressive drugs
Patients receiving chronic treatment with systemic steroids or another immunosuppressive agent.
Patients with known immunodeficiency or receiving immunosuppressive therapies
Use of immunosuppressive therapy within 28 days of starting study treatment. Immunosuppressive therapy includes but is not limited to cyclosporine A, tacrolimus, or high-dose corticosteroids. Subjects receiving corticosteroids must be at a dose level ? 10 mg/day within 7 days of initiating study treatment.
Patients on immunosuppressive therapy including:
Any condition requiring concurrent systemic immunosuppressive therapy
Immunosuppressive disease
Any condition requiring active steroid or other immunosuppressive therapy
Chronic immunosuppressive therapies, including systemic corticosteroids
No concurrent condition resulting in immune compromise, including chronic treatment with corticosteroids or other immunosuppressive agents
Current, active immunosuppressive therapy such as cyclosporine, tacrolimus, etc.
A requirement for chronic systemic immunosuppressive therapy for any reason
Concurrent condition resulting in immune compromise, including chronic treatment with corticosteroids or other immunosuppressive agents
History of organ transplant, or current active immunosuppressive therapy (such as cyclosporine, tacrolimus, etc.).
Receiving ongoing treatment with immunosuppressive drugs, excluding those patients requiring dexamethasone for treatment of tumor-related edema
Immunosuppressive agents (unless required for treating potential AEs)
Receiving ongoing treatment with immunosuppressive drugs, excluding those patients requiring dexamethasone for treatment of tumor-related edema
Patients requiring chronic immunosuppressive therapy (including corticosteroids) for any medical condition
Chronic treatment with systemic steroids or another immunosuppressive agent
Require concurrent treatment with immunosuppressive agents (other than corticosteroids prescribed for a short course of therapy)
Ongoing systemic immunosuppressive therapy other than corticosteroids
Subjects requiring chronic use of immunosuppressive agents (eg, methotrexate, cyclosporine, corticosteroids)
Ongoing immunosuppressive therapy within 14 days prior to the start of study therapy;
Ongoing immunosuppressive therapy other than corticosteroids
Active treatment with corticosteroids or other immunosuppressive agents
Current, active immunosuppressive therapy such as cyclosporine, tacrolimus, etc.
Ongoing immunosuppressive therapy other than corticosteroids
Patient requires chronic use of immunosuppressive agents (e.g. methotrexate, cyclosporine)
Patients must not require chronic use of immunosuppressive agents (e.g. methotrexate, cyclosporine)
Receiving immunosuppressive drugs
Patients requiring continuous, systemic immunosuppressive therapy
Chronic treatment with systemic steroids or another immunosuppressive agent
Need for ongoing treatment with an immunosuppressive agent.
Patients receiving steroids or immunosuppressive therapy for the improvement of hematological parameters (stable steroid treatment for adrenal failure or chronic medical conditions, and intermittent dexamethasone as antiemetics are allowed).
Patients currently treated with systemic immunosuppressive agents, including steroids, are ineligible until 3 weeks after removal from immunosuppressive treatment
Clinically uncontrolled autoimmune disorders, transplant recipients who depend on immunosuppressive therapy, other immunosuppressive conditions including any concurrent condition requiring immunosuppressive/immunomodulating agents;
Use of any systemic immunosuppressive agents
No immunosuppressive therapy within 30 days prior to initiation of protocol therapy
On immunosuppressive therapy.
Increasing or chronic treatment (> 5 days) with corticosteroids or another immunosuppressive agent
Receiving immunosuppressive therapy
Patient is currently receiving increasing or chronic treatment with corticosteroids or another immunosuppressive agent
Subjects on steroid therapy or other immunosuppressive, such as azathioprine or cyclosporin A
Subjects with conditions requiring chronic steroid or immunosuppressive treatment
Chronic treatment with systemic steroids or another immunosuppressive agent
Immunosuppressive therapy within the last 3 months
The patient requires concomitant chronic treatment (more than 7 consecutive days) with systemic corticosteroids or any other immunosuppressive agents.
Patients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent
Subjects with immunosuppressive disease that require use of systemic steroids or immunosuppressive treatment
Patients on chronic immunosuppressive medications, including steroids, within the past three months
Has a diagnosis of an immunosuppressive illness or a condition requiring chronic immunosuppression
Receiving immunosuppressive therapy including chronic steroids, methotrexate, or other known immunosuppressive agents
Need for chronic immunosuppressive drugs
Need for chronic immunosuppressive drugs
Patients who take immunosuppressive medication, i.e. steroid therapy or other immunosuppressive/immunomodulating drugs (e.g. Cyclosporine) within 2 months prior to first study drug injection
Is taking immunosuppressive therapy
Chronic immunosuppressive therapy within 30 days of screening
Patients who have chronic immunosuppression or are on current immunosuppressive therapies
Confirmed or suspected immunosuppressive or immunodeficient condition
Receiving immunosuppressive therapy to include chemotherapy, steroids, or methotrexate
Are immunosuppressed or in chronic use of immunosuppressive drugs.
Subjects on chronic steroid therapy, other immunosuppressive therapy
ongoing chronic immunosuppressive therapy
The participant is receiving therapy with immunosuppressive agents.
The participant is receiving therapy with immunosuppressive agents.
